Article by admin
Esperer Nutrition - Eligere Science
  • Categories

    • No categories
  • Esperer BioResearch launches health supplements for cancer disease management

    Esperer BioResearch launches health supplements for cancer disease management

    The supplements aim to bring optimal efficacy in cancer disease management to ensure better quality of life of patients

    Backed by a strong research on the nutritional deficiencies in cancer patients in India; Esperer BioResearch launched two health supplements Es- Fortitude (nourish, protect &recovery) and Es- Invigour (base formula) in Mumbai. The supplements aim to bring optimal efficacy of the main therapy in cancer disease management to ensure better quality of life of patients across the globe.

    One of the most relevant syndromes that increase as cancer progresses is cachexia that compromises the life of the patient and irremediably causes weakness and death. Hypermetabolism is correlated with clinical and biological markers of cancer cachexia and is associated with a shorter survival in metastatic cancer patients. Thus, there is a need for preparing the body for treatment, during treatment and during recovery stage. All three phases are different and require nutritional care basis the cell biology of the body.

    Amit Srivastava, CEO and Founder, Biovalley Incubation, Responsible Nutrition Association of India; “Patients with cancer cachexia die when there is 25 – 30 per cent of total body weight loss. Depending upon the tumour type, weight loss occurs in 30 to 80 per cent of cancer patients. The incidence of chemotherapy-induced anemia is as high as 100 per cent for grade one to two and 80 per cent for grade three to four anaemia. Most of the cachexia is managed by high whey protein concentrate load given to patient through oral as well as ryles tube. The current whey protein load leads to occurrence of loose motion and compromised uptake of digested protein in form of amino-acids as Indian guts are not primed to cope up with high protein load. This becomes a serious medical concern during chemotherapy as the absorption profile of gut is further compromised. Current market products are flooded by imported or foreign formula of proteins that works well with Caucasian guts.  There is a gap in addressing Indian guts – a scientific product is needed that helps in preventing patient in getting into cachexia without overloading the GI system. Esperer has been incubated as a cancer therapy adjuvant nutrition company at Biovalley Incubation Council that is working on developing a scientific formula that works well for Indian guts in preventing cachexia and reducing chemo load”.

    Raktim Chattopadhyay, Founder and CEO said; “It is our endeavour to work towards a better quality of life for cancer patients. We believe that “Personalised Medicine”  is our chance to revolutionise healthcare. Nutritional imbalance has a direct impact on the cancer disease and our quest is to mitigate the risk that stems from nutritional deficiency in cancer patients.”

    Source: https://www.expresshealthcare.in/news/esperer-bioresearch-launches-health-supplements-for-cancer-disease-management/412253/